Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Olivier Valdenaire is active.

Publication


Featured researches published by Olivier Valdenaire.


Biochimica et Biophysica Acta | 1997

A new functional isoform of the human CRF2 receptor for corticotropin-releasing factor

Olivier Valdenaire; Thomas Giller; Volker Breu; Jürgen Gottowik; Gavin J. Kilpatrick

We have identified the human counterpart of the corticotropin-releasing factor receptor subtype 2beta. Its functional response to human urocortin was demonstrated after stable expression in HEK-293 cells. The receptor was also shown to bind sauvagine, corticotropin-releasing factor and urocortin. In contrast to rodents, the human CRF(2beta) receptor is only weakly expressed in heart and skeletal tissues, where the CRF(2alpha) isoform is predominant. Moreover, we have identified additional mRNAs of the CRF(2beta) type which are probably a consequence of aberrant splicing events.


Trends in Pharmacological Sciences | 1995

An evolutionary view of drug-receptor interaction : the bioamine receptor family

Philippe Vernier; Bruno Cardinaud; Olivier Valdenaire; Hervé Philippe; Jean-Didier Vincent

The large molecular diversity of receptors and their subtypes means that the pharmacologist is faced with many puzzling characterization questions. First, the molecular diversity of the receptors is deciphered only in part by a pharmacological approach, which precludes a satisfactory receptor classification based solely on pharmacological characteristics. Second, the physiological counterpart of the numerous subtypes of receptors specifically activated by single endogenous ligands remains unclear. Here, Philippe Vernier and colleagues use the example of the bioamine G protein-coupled receptors to show that many of the apparent inconsistencies that emerge from pharmacological and molecular characterizations of receptors can be better understood if the evolutionary history of the receptors is taken into account.


Molecular Brain Research | 1999

XCE, a new member of the endothelin-converting enzyme and neutral endopeptidase family, is preferentially expressed in the CNS

Olivier Valdenaire; J. Grayson Richards; Richard L.M. Faull; Anja Schweizer

In the present study, we have isolated a cDNA encoding a novel member of the family of zinc metallopeptidases that includes neutral endopeptidase and endothelin-converting enzyme. The predicted amino-acid sequence of this enzyme, termed XCE, consists of 775 amino-acids with a single putative membrane-spanning region, an N-terminal cytoplasmic domain of 59 residues, and a large luminal domain that contains a characteristic zinc-binding motif. Western blot analysis of cells stably expressing this new metallopeptidase revealed a glycosylated protein of approximately 95 kDa. XCE mRNA was found to be predominantly expressed in the central nervous system, sympathetic ganglia and in uterine subepithelial cells. In the rat and human CNS, a very specific pattern of neuronal labelling (in presumptive cholinergic interneurons of basal ganglia, basal forebrain neurons, as well as brainstem and spinal cord motoneurons) was detected by in situ hybridization histochemistry. The enzyme substrate, as yet unidentified, might be found among the numerous neuropeptide transmitters which are colocalized with acetylcholine in these neurons.


Trends in Pharmacological Sciences | 1998

Isoforms of endothelin-converting enzyme: why and where?

Anthony J. Turner; Kay Barnes; Anja Schweizer; Olivier Valdenaire

A. J. T. and K. B. thank the British Heart Foundation for support of their research on ECE. The authors also thank Dr R. Corder for helpful comments on the manuscript.


Journal of Biological Chemistry | 1999

Neonatal lethality in mice deficient in XCE, a novel member of the endothelin-converting enzyme and neutral endopeptidase family

Anja Schweizer; Olivier Valdenaire; Anja Köster; Yolande Lang; Georg Schmitt; Barbara Lenz; Horst Bluethmann; Jack Rohrer

XCE, a new member of the endothelin-converting enzyme and neutral endopeptidase family, is preferentially expressed in specific areas of the central nervous system including spinal chord and medulla. To elucidate the importance and function of XCE, we disrupted its gene in mouse embryonic stem cells by homologous recombination and created mice deficient in XCE. The resulting phenotype is characterized by neonatal lethality. All XCE −/− homozygous mice died of respiratory failure shortly after birth, and in most cases their lungs were never ventilated. Apart from the atelectasis, anatomical and histological examinations of embryonic day 18.5 XCE −/− embryos and newborn homozygotes did not reveal any obvious abnormalities in organs and tissues. Malformations that are related to the knock-out were also not found in the skeletons of XCE −/− mice. In addition, XCE knock-out animals showed no deficiency of pulmonary surfactant proteins and had normal heart beat frequencies. Taken together, our results demonstrate that XCE is an essential gene. The phenotype of the XCE-deficient mice together with the central nervous system-specific expression further suggest that XCE may play a vital role in the control of respiration.


Journal of Neurochemistry | 2002

Retinoic Acid Regulates the Developmental Expression of Dopamine D2 Receptor in Rat Striatal Primary Cultures

Olivier Valdenaire; Marion Maus-Moatti; Jean-Didier Vincent; Jacques Mallet; Philippe Vernier

Abstract: The time course of D2 receptor expression assessed by the levels of the corresponding binding sites and mRNA was studied in rat striatum during ontogenesis and in primary cultures of cells taken at embryonic day (E) 17 and postnatal day (P) 4. In the two experimental situations, the amount of D2 receptor mRNA and number of binding sites increased regularly from E16 to P15, indicating that expression of D2 receptors in striatal neurons occurs independently from a dopaminergic input. Incubation of striatal primary cultures with 10−5M retinoic acid significantly increased the level of D2 receptor mRNA, whereas thyroid hormone, vitamin D3, and steroid hormones (estradiol, testosterone, and corticosterone) had no effect. The transcriptional activity of the rat D2 receptor gene promoter region, which bears a retinoic acid‐responsive element, was increased by retinoic acid in transfected C6 glioma cells but not in transfected MMQ prolactin cells. Thyroid hormone and vitamin D3 were not effective in either cell line. Finally, mutations of the putative retinoic acid‐responsive element inhibited the transcriptional effect of retinoic acid. These results suggest that retinoic acid is a key factor in regulation of the embryonic onset of the dopaminergic D2 receptor.


Neuropharmacology | 1999

Human CRF2 α and β splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay

Ali Ardati; Valerie Goetschy; Juergen Gottowick; Stephane Henriot; Olivier Valdenaire; Ulrich Deuschle; Gavin J. Kilpatrick

Abstract Corticotropin releasing factor (CRF) receptors belong to the super-family of G protein-coupled receptors. These receptors are classified into two subtypes (CRF1 and CRF2). Both receptors are positively coupled to adenylyl cyclase but they have a distinct pharmacology and distribution in brain. Two isoforms belonging to the CRF2 subtype receptors, CRF2α and CRF2β, have been identified in rat and man. The neuropeptides CRF and urocortin mediate their actions through this CRF G protein-coupled receptor family. In this report, we describe the pharmacological characterization of the recently identified hCRF2β receptor. We have used radioligand binding with [125I]-tyr0-sauvagine and a gene expression assay in which the firefly luciferase gene expression is under the control of cAMP responsive elements. Association kinetics of [125I]-tyr0-sauvagine binding to the hCRF2β receptor were monophasic while dissociation kinetics were biphasic, in agreement with the kinetics results obtained with the hCRF2α receptor. Saturation binding analysis revealed two affinity states in HEK 293 cells with binding parameters in accord with those determined kinetically and with parameters obtained with the hCRF2α receptor. A non-hydrolysable GTP analog, Gpp(NH)p, reduced the high affinity binding of [125I]-tyr0-sauvagine to both hCRF2 receptor isoforms in a similar manner. The rank order of potency of CRF agonist peptides in competition experiments was identical for both hCRF2 isoforms (urocortin>sauvagine>urotensin 1>r/hCRF>α-helical CRF(9–41)>oCRF). Similarly, agonist potency was similar for the two isoforms when studied using the luciferase gene reporter system. The peptide antagonist α-helical CRF(9–41) exhibited a non-competitive antagonism of urocortin-stimulated luciferase expression with both hCRF2 receptor isoforms. Taken together, these results indicate that the pharmacological profiles of the CRF2 splice variants are identical. This indicates that the region of the N-terminus that varies between the receptors is probably not important in the binding of peptide CRF receptor ligands or functional activation of the receptor.


FEBS Letters | 1998

A new family of orphan G protein‐coupled receptors predominantly expressed in the brain1

Olivier Valdenaire; Thomas Giller; Volker Breu; Ali Ardati; Anja Schweizer; J. Grayson Richards

The cloning of a cDNA encoding a G protein‐coupled receptor homologous to the endothelin type B receptor, but unable to bind endothelin, was recently reported and termed ETBR‐LP. We report here the isolation of a human cDNA encoding a receptor that is highly related to ETBR‐LP and which was therefore termed ETBR‐LP‐2. Comparison of the two amino acid sequences revealed 68% overall homology and 48% identity. As is the case for ETBR‐LP, the new receptor is strongly expressed in the human central nervous system (e.g. in cerebellar Bergmann glia, cerebral cortex, internal capsule fibers). Membranes of HEK‐293 cells stably expressing ETBR‐LP‐2 did not bind endothelin‐1, endothelin‐2, endothelin‐3, bombesin, cholecystokinin‐8 or gastrin‐releasing peptide.


Cell and Tissue Research | 1999

The endothelin system in human and monkey ovaries: in situ gene expression of the different components

Habib Karam; Olivier Valdenaire; Marie-France Belair; Caroline Prigent-Sassy; Annette Rakotosalama; Martine Clozel; Joseph Itskovitz; Patrick Bruneval

Abstract The endothelin system is composed of three endothelin isoforms (ET-1, ET-2, and ET-3), the endothelin receptors ETA and ETB, and the endothelin-converting enzyme (ECE). Besides having a major vasoactive role, endothelins have roles in different cell types at a local level. We investigated the presence of the different components of the endothelin system in primate ovaries. Human ovaries and gonadotropin-stimulated monkey ovaries were studied using immunohistochemistry for endothelin, and in situ hybridization with probes for ET-1, ET-2, ET-3, ETA and ETB receptors, and ECE. ET-1 and ETA receptors were detected in endothelial cells and vascular smooth muscle cells, respectively, in stromal vessels adjacent to follicles and corpora lutea. ETB receptors and ET-1 were found in the endothelial cells of capillaries of corpora lutea. ECE was present in internal theca cells of secondary, de Graaf, atretic follicles, and in luteinized granulosa cells of the corpora lutea. The endothelin system components are present in or around the follicles of human and monkey ovaries. Although the components are not expressed in the same cell types, they are synthesized, mainly in follicles, by cells that are in close proximity. Thus, the endothelin system could act in a paracrine manner. ECE expression in steroid-producing cells changes its compartmentalization during follicle maturation.


Life Sciences | 1997

ABSENCE OF ETB-MEDIATED CONTRACTION IN PIEBALD-LETHAL MICE

Thomas Giller; Volker Breu; Olivier Valdenaire; Martine Clozel

Activation of the endothelin (ET) ET(B) receptor can mediate opposite effects, endothelium-dependent vasodilation but also direct vasoconstriction. So far one gene encoding an ET(B) receptor has been identified and associated with endothelium-dependent relaxation. It has been suspected that the presence of another ET(B) gene could explain ET(B)-mediated contraction. The goal of the present study was to evaluate in Piebald-lethal (s[1]) mice, a naturally occurring mutant with deletion of the known ET(B) receptor gene, whether ET(B) receptor-mediated constriction is lost. Piebald-lethal (s[1]) mice, in contrast to control mice, completely lacked ET(B) specific ligand binding. The pressor effect of the ET(B) receptor selective agonist sarafotoxin S6c was completely absent. In vitro, contraction of stomach strips induced by sarafotoxin S6c was also abolished in Piebald-lethal (s[1]) mice. These results demonstrate the responsibility of the known ET(B) receptor gene in ET(B)-mediated constriction.

Collaboration


Dive into the Olivier Valdenaire's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Philippe Vernier

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge